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Abstract During the past decade, the identification of
microRNA (miR) targets has become common laboratory
practice, and various strategies are now used to detect
interactions between miRs and their mRNA targets. How-
ever, the current lack of a standardized identification
process often leads to incomplete and/or conflicting results.
Here, we review the problems most commonly encountered
when verifying miR–mRNA interactions, and we propose a
workflow for future studies. To illustrate the challenges
faced when validating a miR target, we discuss studies in
which the regulation of brain-derived neurotrophic factor
by miRs was investigated, and we highlight several con-
troversies that emerged from these studies. Finally, we
discuss the therapeutic use of miR inhibitors, and we dis-
cuss several questions that should be addressed before
proceeding to preclinical testing.
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Abbreviations
AD Alzheimer’s disease
AM AntagomiR
ARPE-19 Human artificial retinal pigment epithelial
cells
bEnd.3 Immortalized mouse brain endothelial cell
line
BDNF Brain-derived neurotrophic factor
C2C12 Mouse myoblast cell line
ChIP-seq Chromatin immunoprecipitation combined
with massively parallel DNA sequencing
H9c2 Rat cardiac myoblast cell line
HEK-293 Human embryonic kidney cell line
HeLa Human cervical cancer cell line
HUVEC Human umbilical vein endothelial cells
LNA Locked nucleic acid
MCF7 Michigan Cancer Foundation-7 human breast
cancer cell line
miR MicroRNA
MRE MicroRNA response element
Neuro2a Mouse neuroblastoma cell line
NG108-15 Hybrid cell line from fused mouse
neuroblastoma and rat glioblastoma cells
SCG7901 Human gastric cancer cell line
SH-SY5Y Human neuroblastoma cell line
U-87 MG Human glioblastoma cell line
UTR Untranslated region
Introduction
MicroRNAs (miRs) are short noncoding RNA molecules
that bind their target mRNA via a short (6–8 mer) seed
sequence located in their 50 end (Fig. 1); upon binding, the
miR regulates the target gene’s expression by destabilizing
the mRNA and/or inhibiting its translation [1–6]. The
following requirements for canonical interactions between
a miR and its mRNA target sequence have been estab-
lished: (1) the seed sequence must be fully complementary
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to the miR response element (MRE) for the miR to exert its
effect; (2) as a general rule, 8-mer seed sites are more
effective than 7-mer or 6-mer sites [7–9], although other
means of target recognition—such as base-pairing in the
central region of the miR [10] or tolerance of loops in the
mRNA–miR duplex [11]—have been described; (3) 30
complementarity between the miR and its mRNA target
can facilitate repression of the target mRNA [11]; (4) in
general, evolutionarily conserved MREs are regulated
more effectively by miRs [7]; and (5) local sequence
context—in particular, the density of adenine (A) and
uracil (U) nucleotides—influences the functionality of the
predicted miR-binding site [9].
These properties enable researchers to generate com-
putational algorithms that can be used to predict the
interaction between a miR and its potential target(s).
Importantly, however, some target sites with a high like-
lihood of being regulated by miRs (i.e., evolutionarily
conserved 8-mer MRE sites) do not respond to miRs (based
on luciferase reporter assays and measuring mRNA and
protein levels) [9, 12]. Furthermore, the current level of
knowledge does not enable researchers to incorporate the
mRNA secondary structure or three-dimensional confor-
mation into the target prediction process, nor can
researchers take into account potential interactions with
RNA-binding proteins that may render a predicted site
inaccessible to the miR [9, 13]. An evaluation of various in
silico methods for predicting miR targets has revealed that
even algorithms with high specificity fail to accurately
predict more than 50 % of targets (reviewed in [14]),
underscoring the need to experimentally verify each pre-
dicted interaction.
Here, we will first discuss briefly the methods used to
verify miR targets, and some of the aspects of the experi-
mental setup that may influence the outcome and/or
reproducibility of the experiments. Next, we illustrate the
above-mentioned factors by reviewing published studies
regarding brain-derived neurotrophic factor (BDNF) and
miR interactions, and we propose a workflow for future
studies aimed at improving the strength and reliability of
the results. Finally, we highlight several open questions
related to translating current knowledge to preclinical
testing.
Materials and methods
The superior cervical ganglia were dissected from P1
NMRI mice, dissociated, and cultured for 14 days on a
laminin-coated dish in Neurobasal medium supplemented
with 2 % B-27, 0.5 mM L-glutamine, 0.2 % Primocin, and
30 ng/ml mouse nerve growth factor (#G5141; Promega).
Immediately prior to microinjection, the medium was
changed to Leibovitz’s-L15 medium (#11415-06,4; Life
Sciences) supplemented with 30 ng/ml mouse nerve
growth factor. The cells were microinjected with the fol-
lowing antagomiR oligos: a 21-mer phosphodiester
oligonucleotide containing a 30-FAM (carboxyfluorescein)
label (#199005-08; Exicon) or a 21-mer phosphorothioate
oligonucleotide containing a 50-FAM label (#199002-04;
Exicon); both oligonucleotides contained several LNA
bonds. The antagomiRs were designed with a sequence that
is not complementary to any know miRs in human or
mouse cells. The antagomiRs were diluted to 10 lM in
phosphate-buffered saline containing 2 mg/ml 70-kDa
dextran conjugated to Texas Red (#D1830, Molecular
Probes) and injected into the cytoplasm of the neurons.
Images were taken immediately after injection and at the
indicated time points, and the images shown in Fig. 4 are
representative of six successfully injected neurons for each
antagomiR.
Screening miR–mRNA interactions using the luciferase
reporter assay
Reporter assays are commonly used as the first step in
validating the interaction between miRs and target
mRNAs; these assays are usually based on a luciferase-
encoding gene derived from the sea pansy (Renilla reni-
formis) or a Photinini firefly (e.g., Photinus pyralis). In
most cases, the 30UTR fragment containing the MRE of
interest is cloned downstream of a luciferase gene, and this
reporter construct is then co-transfected into a cell line
together with the pre-miR. Target recognition is presumed
to have occurred if the miR in question affects the lucif-
erase signal differently than a control miR that lacks a
predicted binding site within the reporter. However, often a
fragment of the 30UTR fragment—rather than the entire
30UTR—is used to identify candidate miR targets, which
can lead to false-positive or false-negative results. The
secondary structure of a short 30UTR fragment likely dif-
fers from the structure of the full-length 30UTR,
particularly if the full-length 30UTR is long, which is the
Fig. 1 Schematic of a miR binding to its MRE within the target
mRNA. The second miR-1-binding site in the BDNF 30UTR is used as
an example. The miR seed sequence (the nucleotides at positions 2
through 8) is shown in red, and the miR-binding site (MRE) in the
30UTR is shown in blue. The arrows depict 30 supplementary base-
pairing. MRE miR responsive element, BDNF brain-derived neuro-
trophic factor, CDS coding DNA sequence
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case with the majority of genes predicted to be regulated by
miRs [15]. Thus, a site that would normally be inaccessible
to miRs may become available if a short fragment of the
30UTR is used, yielding false-positive ‘‘hits’’; alternatively,
an accessible site may become inaccessible, yielding a
false-negative result [9]. In addition, the structure of the
reporter gene’s mRNA can influence the structure of the
30UTR being studied, advocating the use of several
reporters (for example, luciferase genes obtained from both
Renilla reniformis and Photinus pyralis) in the assay.
Finally, it is important to note that transient transfection
usually yields high intracellular concentrations of the
complementary molecules, which can drive interactions
that would not occur under physiological conditions [16].
Therefore, additional strategies such as validating the
direct interaction, overexpressing the miR, and/or sup-
pressing the expression of endogenous miR should be used
to be able to conclude that a given mRNA is indeed a target
of the miR under study.
Analysis of endogenous miR–target interactions
miRs can be overexpressed using miR precursors (pre-
miRs), viral miR or pre-miR expression, plasmids encoding
pre-miRs, or cell lines that stably overexpress miRs. Ide-
ally, such studies should include verification that the
introduced miR is expressed at increased levels. If the
target transcript is indeed regulated by the miR in question,
overexpression of the miR should decrease the target gene
expression.
The expression and/or effect of a miR can be suppressed
using chemically modified antisense nucleotides [17–19],
and other approaches—such as miR sponges [20], target
site protectors [21, 22], and miR ‘‘touch decoys’’ [23,
24]—are also available. If the target is regulated by an
endogenous miR, and if this miR is expressed in the cells,
inhibiting the miR should increase the target gene expres-
sion levels. Based on the above-mentioned factors, these
complementary approaches are necessary in order to con-
firm that miRs identified using the luciferase assay regulate
their target genes under physiological conditions. Impor-
tantly, because the mRNA and protein levels of individual
genes are not necessarily correlated, both levels should be
measured when a miR is overexpressed or suppressed.
Selecting the model system to analyze endogenous
miR–target interactions
Selecting a cell-based model to assess the effects of miRs
on their targets is not trivial. Because primary cell cultures
are more likely to recapitulate in vivo conditions, they are
clearly superior to cell lines in terms of assessing miR–
target interactions in a physiological context. However,
preparing primary cultures can be both time-consuming
and labor-intensive, and difficulties delivering the miR—
coupled with potentially low expression of the putative
targets—may complicate the analysis of miR–target inter-
actions. For these reasons, immortalized cell lines are often
used in in vitro studies. Nevertheless, it is important to bear
in mind that cell lines derived from cancerous tissues can
have aberrant levels of gene expression, which will likely
affect miR-mediated target regulation. For example, the
results could be affected by the presence or absence of
RNA-based or protein-based cofactors necessary for miR
binding, or by the presence of RNA-binding proteins that
modulate site accessibility. Furthermore, many of the genes
that are subject to miR-mediated suppression are regulatory
in nature [15], and their temporally and/or spatially com-
plex expression pattern is not necessarily recapitulated in a
cell line grown under fixed culture conditions. Thus, when
previous knowledge regarding the function of the target
gene is known, the preferred approach is to choose a cell
line that is likely to retain at least some of the original
tissue’s ‘‘normal’’ gene expression profile. Moreover, sev-
eral cell lines can be used, thereby minimizing the
likelihood of identifying false-positive and/or false-nega-
tive interactions.
In addition to choosing the optimal cell culture system,
the experimental timeframe is also likely to influence the
outcome of miR transfection. For example, it can take
8–10 h to maximally load Argonaute proteins (a family of
proteins that direct miR–target binding and subsequently
block translation and/or mRNA cleavage) with small RNAs
[25]. Furthermore, the median half-life of mRNAs and
proteins is 9 and 46 h, respectively [26]; therefore, mild
changes in gene expression following miR transfection
may not be detectable if the change is measured too early
after transfection (e.g., under 24 or even 48 h), particularly
when measuring protein levels.
Validation of the direct interaction
Although performing miR overexpression and miR inhi-
bition experiments are important steps in verifying miRs as
regulators of candidate genes, these experiments do not
reveal whether an observed change in target gene levels is
the result of direct binding between the miR and the pre-
dicted site in the 30UTR. This can be analyzed in a
luciferase assay by co-expressing the miR and the 30UTR
containing a mutated MRE site. Unfortunately, however,
direct miR–mRNA interactions are tested only rarely. To
illustrate this point, Table 1 summarizes the data collected
to date from BDNF mRNA–miR studies. Despite the pre-
sence of a putative conserved binding site within a given
gene, the responsive 30UTR might still be regulated indi-
rectly by other targets of the miR. Furthermore, several
miR target validation: focus on BDNF 1781
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Table 1 Current knowledge regarding the regulation of the 30UTR of the BDNF mRNA by miRs based on studies that used a luciferase reporter assay
MicroRNA 30UTR sequence used Effect on luciferase signal in the reporter
assay
Direct interaction shown References
miR-1 Long and short 30UTR ;b Yes (sites #1 and #2 are
functional)
[27]
Synthetic oligoa ;b Yesh [77]
miR-10b Long and short 30UTR ;b Yes [27]
miR-15a Long and short 30UTR No effectb n.d. [27]
855-nt 30UTR fragment ;c n.d. [94]
miR-16 Long and short 30UTR No effectb n.d. [27]
miR-22 Long 30UTR ;d n.d [95]
miR-26a,
26b
Long 30UTR, including ca 30 nt of the
CDS
;d Yes [96]
miR-30a Long and short 30UTR No effectb n.d [27]
552-nt 30UTR fragment ;b n.d [97]
miR-30b Long and short 30UTR No effectb n.d [27]
552-nt 30UTR fragment No effectb n.d [97]
miR-30c 552-nt 30UTR fragment No effectb n.d [97]
miR-107 552-nt 30UTR fragment No effectb n.d [97]
miR-138-2 Long 30UTR No effectd n.d [95]
miR-155 Long and short 30UTR ; (long 30UTR only)b yes [27]
miR-182 Long and short 30UTR No effectb n.d [27]
miR-191 Long and short 30UTR ; (long 30UTR only)b yes [27]
469-nt 30UTR fragment :e n.d [84]
552-nt 30UTR fragment No effectb n.d [97]
miR-195 Long and short 30UTR No effectb n.d [27]
Not specified No effectf n.d [82]
552-nt 30UTR fragment ;b n.d [97]
miR-204 Long 30UTR ;b Yes [92]
miR-206 Long 30UTR ;c Yes (sites #1, #2 and #3 are
functional)
[83]
Not specified ;f n.d [82]
Long 30UTR (human), 30UTR fragments
(mouse)
; (long 30UTR and fragment containing
site #3)d
Yes (only site #3 is functional) [81]
Short 30UTR, 478 nt and 1,355 nt 30UTR
fragments
No effect (short 30UTR), ; (long 30UTR
fragment)g
Yes (sites #1 and #2 are
functional)
[80]
1,500-nt 30UTR fragment ;c n.d [79]
1,057-nt 30UTR fragment No effectg n.d [78]
miR-210 60-nt 30UTR fragment ;b Yes [93]
miR-339 Long 30UTR No effectd n.d [95]
miR-376b-
5p
30UTR fragment, size not specified ;c n.d [100]
miR-497 Not specified No effectf n.d [82]
n.d not determined
a Synthetic oligo with no similarity to BDNF mRNA containing three sites complementary to miR-1 binding site
b HEK-293 cells
c HEK-293T cells
d HeLa cells
e MCF7 cells
f SH-SY5Y cells
g C2C12 cells
h Shown using miR-1-binding site mutations in a synthetic oligonucleotide with no similarity to BDNF mRNA
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studies have used a strategy in which miR seed sites are
mutated and the effect on a reporter or endogenous gene is
compared to the effect of the wild-type miR. Although
demonstrating that the mutated miR has no effect on the
target gene indicates that the target gene is regulated by the
miR in question, such an experiment does not necessarily
confirm that the miR interacts directly with the given
30UTR. In this respect, the results are no more informative
than results obtained from either exogenous miR overex-
pression or miR suppression. Therefore, the predicted MRE
site in the 30UTR should be mutated in the reporter con-
struct in order to determine whether the effect of the miR is
direct or indirect.
A direct interaction between an endogenous miR and its
target can also be confirmed using target site protectors that
are designed to specifically prevent the miR from binding
to its predicted target site in the 30UTR [21, 22]. Although
target site protectors have been described to prevent
binding of the miR to its target in vivo [21], they are
currently not widely used. We attempted to study the
regulation of endogenous BDNF by endogenous miRs
using morpholino antisense oligos as target site protectors;
these oligos were designed to prevent the binding of miR-1
and miR-10b to the 30UTR of the BDNF mRNA. We
previously identified binding sites for miR-1 and miR-10b
in the 30UTR of BDNF and found that these sites act as
direct regulators of BDNF via its 30UTR [27]. However,
target site protectors that mask the same sites had no effect
on endogenous BDNF mRNA or BDNF protein levels.
Thus, due to steric and/or other factors, morpholino oligos
may not be effective at inhibiting all potential miR–target
interactions. Despite the clear advantage of enabling gene-
specific de-repression, the relative paucity of published
studies that use target site protectors suggests that this
method needs further development.
In addition, immunoprecipitation methods can be used to
identify the target mRNAs of endogenous miRs [28]. For
example, a genome-wide screen using Argonaute immuno-
precipitation followed by high-throughput RNA sequencing
identified thousands of putative endogenous miR–target
interactions in the mouse brain [29] and in HEK-293 cells
[30]. Although these results require validation using other
methods, Argonaute immunoprecipitation followed by tar-
get mRNA detection methods (e.g., qPCR-based detection of
the predicted target mRNA levels following pre-miR over-
expression) might be a valuable tool for use in future studies.
Furthermore, microarray and RNA-seq analyses of gene
expression in cell lines following miR transfection/knock-
down have provided additional information regarding
potential miR–target interactions [3, 12, 31–34]. Together,
the above-mentioned high-throughput datasets, which are
currently available at http://servers.binf.ku.dk/antar/ [34],
may serve as a valuable starting point for future studies.
Measuring the concentration of endogenous miRs
and their targets
The absolute levels of endogenous miRs and their pre-
dicted target transcripts can play a significant role in the
degree of the target genes’ downregulation by miRs. For
example, miRs that are expressed at low levels are gener-
ally ineffective at suppressing their predicted targets [35].
Therefore, the physiological relevance of verified miR–
target interactions should be assessed by analyzing the ratio
of the miR to its target mRNA in specific tissues and/or cell
types.
On the other hand, a recent study found that the ability
of a miR to suppress the expression of individual targets is
not necessarily correlated to its expression level [36].
Indeed, the total number of available target transcripts can
affect the potential of a miR to reduce the level of its
targets. Specifically, miRs that have a high number of
available target transcripts suppress each individual target
to a lesser extent than miRs that have a smaller number of
available targets [37]. Therefore, knowing the absolute
levels of a given miR and its target mRNA may not be
sufficient without knowing the expression of other tran-
scripts that the miR might target. Thus, the absolute
expression levels of the miR and its putative target in the
analyzed cell type or tissue do not necessarily confirm or
preclude the possibility that their interaction is physiolog-
ically significant in a specific context, and this should be
investigated experimentally. Nevertheless, the miR and
mRNA expression levels can be used to estimate the
likelihood of such interactions.
Endogenous mRNA transcripts can be quantified rel-
atively easily using real-time RT-PCR [38]. On the other
hand, measuring the number of endogenous miR copies
appears to be more challenging, given their relatively
short length. RT-PCR-based miR quantification [39–41]
is both cost-effective and suitable for analyzing a small
number of miRs simultaneously; however, it is not effi-
cient enough for use on a genomic scale. In contrast,
high-throughput methods such as microarray hybridiza-
tion [42] and next-generation sequencing [43] allow
researchers to analyze hundreds of miRs simultaneously,
but these methodologies tend to be relatively expensive.
It is also important to note that the values of the mea-
sured miR levels can vary considerably depending on the
technology used, which suggests that miR levels should
be quantified using several approaches in order to
increase reliability of the results [44]. Finally, databases
containing information regarding miR expression levels
in various tissues and cell types are continuously being
expanded, and these valuable resources can be used to
estimate the magnitude of a given miR expression in a
given site.
miR target validation: focus on BDNF 1783
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Assessing the cooperative effects of miRs
Finally, problems related to identifying and validating the
target can arise because miRs often exert only a mild
effect on the expression of their targets [3, 12, 45]. In
other words, small changes in gene expression (i.e., on
the order of 5–10 %) can be difficult to characterize as
significant and/or functionally important. In addition,
assessing the effect of a combination of miRs—each of
which may exert only a small effect on the expression of
a specific gene—can be challenging. Importantly, studies
have shown that several miR sites within a single 30UTR
can repress gene expression synergistically [9, 46, 47].
To investigate the possible synergistic effect of multiple
endogenous miRs on the regulation of a given target, the
seed sequences of the validated miR-binding sites can be
mutated alone or in combination, and this can be fol-
lowed by a luciferase assay without the addition of
exogenous miRs. This approach was used successfully to
demonstrate that four miR-binding sites in the 30UTR of
BDNF are used synergistically by endogenous miRs to
regulate the expression of BDNF [27]. Because miRs
often act in concert to regulate individual targets [48], an
analysis of the cooperative effect of miRs (for example,
by replacing the gene’s 30UTR with a 30UTR that lacks
predicted miR binding sites or by mutating most of the
validated miR sites) is needed in order to obtain a more
thorough understanding of how the gene expression is
regulated by miRs, particularly in a physiological
context.
In summary, several complementary approaches can be
used to verify miR–target interactions, and these approa-
ches can support the finding that a given mRNA is
regulated by one or more specific miRs. Below, we illus-
trate and expand upon the above-mentioned points by
summarizing and discussing the existing knowledge
regarding the interaction between the BDNF mRNA and
miRs.
Lessons from studies on BDNF
Brain-derived neurotrophic factor (BDNF) is a target-
derived neurotrophic factor that promotes the survival of
several types of central and peripheral neurons [49–51].
BDNF plays a key role in the development and function of
the nervous system, including synaptic plasticity, learning,
and memory. Although knocking down the expression of
BDNF in vitro has relatively few consequences, even a mild
change in BDNF levels can have severe consequences
in vivo. For example, heterozygous BDNF-knockout mice
have deficits in striatal dopamine output [52], long-term
potentiation [53, 54], hippocampal learning [55], and pre-
synaptic GABAergic function [56]. Changes in BDNF
levels have also been implicated in a variety of neuropsy-
chiatric disorders, including Alzheimer’s disease [57, 58],
bipolar disorder [59–61], schizophrenia [62–66], and
depression [67–69]. Outside of the brain, increased BDNF
expression is believed to contribute to several processes,
including the generation and maintenance of neuropathic
pain [70, 71] and muscle regeneration following injury [72].
miR-mediated regulation of BDNF expression
The BDNF mRNA contains two alternative polyadenylated
transcription stop sites, yielding two pools of transcripts
that differ with respect to the length of the 30UTR; the long
BDNF transcript contains a *3,000-nt 30UTR, whereas the
short BDNF transcript contains a *350-nt 30UTR (Figs. 2,
3) [73]. Interestingly, several predicted miR-binding sites
are located exclusively in the long 30UTR, providing a
possible mechanism for miRs to differentially regulate the
two mRNA isoforms (Fig. 2).
According to various target prediction programs,
BDNF is potentially regulated by several hundred miRs
via its 30UTR. To date, however, only approximately 25
miRs have been investigated experimentally, each to a
different extent (Fig. 2). Of the 25 potential BDNF
Fig. 2 Schematic of miR-binding sites in the 30UTR of the BDNF
mRNA. The miR-binding sites shown in red have been validated as
direct regulators of BDNF expression; the sites shown in black have
been experimentally demonstrated as possible BDNF regulators, but
have not been validated. The red arrows indicate alternative
polyadenylation sites. The three predicted binding sites for miR-1/
206 (1/206 #1, 1/206 #2, and 1/206 #3) are indicated. Note that the
miR-376b-5p binding site is present in the rat and mouse 30UTR, but
not in the human 30UTR
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mRNA–miR interactions studied, approximately one-third
have been analyzed by mutating the MRE and have been
confirmed as direct interactions (the red lines depicted in
Fig. 2). Below, we discuss our current knowledge
regarding the regulation of BDNF expression by miRs
and the currently unresolved issues.
Fig. 3 Schematic showing the 30UTR fragments of the BDNF mRNA
that were used to study BDNF–miR interactions. Only studies in
which the size of the 30UTR fragment was reported are included. The
binding sites for the miRs examined in each study are shown in red.
The alternative transcription stops and polyadenylation sites that yield
two distinct BDNF mRNA isoforms (i.e., containing a short and long
30UTR) are indicated with red arrows. NM_170735.5 refers to human
BDNF mRNA, transcript variant 1, NCBI reference sequence.
H human 30UTR, M mouse 30UTR, R rat 30UTR, Asterisk miR-
binding site present only in humans
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miR-1
miR-1 is an evolutionarily conserved member of the miR-
1/206 family and is expressed specifically in muscle tissue
[74–76]. Based on sequence prediction, the 30UTR of the
BDNF mRNA contains three putative binding sites for
miR-1; one binding site is located in the short 30UTR, and
two sites are located in the long 30UTR (Fig. 2).
Using the full-length long and short BDNF 30UTR iso-
forms in a luciferase expression assay, we recently found
that miR-1 can inhibit luciferase expression via both iso-
forms. Mutation analysis revealed that the first two
predicted binding sites are used by miR-1; in contrast,
mutating the third site did not affect the luciferase signal
compared to the wild-type 30UTR [27]. Given that miR-
binding sites located near the center of the 30UTR are
generally less effective than sites located at either end of
the 30UTR [9], we hypothesize that the third site, which is
located at the center of the BDNF 30UTR, may not be
accessible to miR-1 due to the mRNA secondary structure.
We also measured endogenous BDNF expression in human
artificial retinal pigment epithelial (ARPE-19) cells, which
produce high levels of BDNF. Following treatment with pre-
miR-1, both the intracellular and secreted BDNF protein
levels were reduced. Interestingly, we observed no change in
BDNF mRNA levels, suggesting that miR-1 may suppress
BDNF production at the level of protein synthesis [27].
The effect of miR-1 on BDNF expression was also
examined in another recent study, which found that over-
expressing miR-1 in U-87 MG cells (a human primary
glioblastoma line) caused a 50 % decrease in BDNF pro-
tein levels [77]. The authors used a luciferase assay and
transfected a 60-nt synthetic oligonucleotide containing
three sites complementary to the miR-1 seed sequence
flanked by a sequence that was not related to the BDNF
30UTR. Mutating the three miR-1 sites increased the
luciferase signal compared to a construct containing wild-
type miR-1 sites. The authors concluded that their results
support a direct interaction between miR-1 and the 30UTR
of BDNF [77]. However, because the reporter construct
contained no adjacent sequences of the BDNF mRNA, not
to mention the full-length 30UTR, the observed interaction
might not be specific to BDNF, but might reflect the ability
of a miR to bind to and inhibit its MRE.
miR-206
miR-206 is in the same miR family as miR-1 and shares the
same predicted binding sites in the 30UTR of the BDNF
mRNA (Fig. 2). Outside of the seed region, miR-1 and miR-
206 differ by only four nucleotides. Several studies have used
luciferase reporter assay to investigate the ability of miR-206
to regulate BDNF mRNA via its 30UTR [78–83]. However,
the results obtained to date have been contradictory, and this
is likely due to differences in experimental design (see Fig. 3;
Table 1). For example, using a luciferase construct containing
a 1,057-nt fragment with part of the BDNF coding sequence
and only the most proximal miR-206 binding site in the
30UTR, Kim et al. [78] concluded that miR-206 does not
suppress BDNF expression via its 30UTR, although endoge-
nous BDNF mRNA levels were reduced after treating C2C12
cells with miR-206. In contrast, Radzikinas et al. [79] found
that a 1,500-nt BDNF mRNA 30UTR fragment (containing all
three predicted miR-206 binding sites) was suppressed by
miR-206. Moreover, Miura et al. [80] found that the short
30UTR of BDNF was not regulated by miR-206, whereas a
luciferase construct containing 1,355-nt 30UTR fragment
(including all three binding sites) was suppressed by miR-
206. In the same study, mutation analysis revealed that
mutating each site independently had no effect on the miR-
206–induced suppression of the BDNF 30UTR, whereas
mutating the first two sites together prevented miR-206–
induced inhibition. Interestingly, Lee et al. [81] reached the
opposite conclusion based on their finding that the full-length
30UTR was inhibited by miR-206, whereas an analysis of the
three binding sites using short mutant 30UTR fragments
revealed that only the third site was functional. Finally, a
study by Tapocik et al. [83] provided evidence that miR-206
mediates suppression via all three putative binding sites in the
full-length 30UTR.
In summary, a clear consensus is currently lacking
regarding the effect of miR-206 on the long 30UTR of the
BDNF mRNA, and the function of each predicted binding
site differs among studies. Therefore, it is highly likely that
the use of different length 30UTR fragments (rather than the
full-length 30UTR) contributes significantly to the contra-
dictory results obtained from these studies. Thus, until we
thoroughly understand the three-dimensional structure of
the 30UTR (and its effect on the miR-mRNA interaction),
data obtained from fragments of the 30UTR should not be
used to draw conclusions based on the full-length 30UTR.
Interestingly, experimental evidence suggests that the
short 30UTR of BDNF may not be regulated by miR-206
[78, 80], despite the presence of a putative binding site. This
finding warrants further attention, as miR-1—which shares
an MRE with miR-206 but differs from miR-206 by only
four nucleotides outside the seed sequence—does suppress
BDNF mRNA via the short 30UTR [27]. Thus, future studies
of the BDNF 30UTR may yield further insight regarding how
the sequence and secondary structure of the mRNA regulate
the effects of miRs on their specific target.
miR-10b
We recently reported that miR-10b has a single, highly
conserved 8-mer binding site in the short 30UTR of the
1786 K. Varendi et al.
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BDNF mRNA. Using a luciferase assay, we found that
miR-10b suppressed reporter expression via both the long
and short 30UTRs of BDNF; moreover, mutating the
putative binding site in the long 30UTR abolished sup-
pression induced by overexpressed miR-10b and
endogenous miR-10b. In addition, we used ARPE-19 cells
to show that endogenous BDNF mRNA and BDNF protein
levels are: (1) decreased following transfection with pre-
miR-10b and (2) increased after endogenous miR-10b was
downregulated using an antagomiR that targets miR-10b.
Taken together, these data suggest that miR-10b is a direct
regulator of BDNF expression [27].
miR-155 and miR-191
Both miR-155 and miR-191 have predicted binding sites in
the long 30UTR of the BDNF mRNA (Fig. 2). Using a
luciferase assay, we recently reported that both miR-155
and miR-191 specifically reduce the expression of a
luciferase construct containing the BDNF long 30UTR but
not the short 30UTR. Moreover, mutation analysis revealed
that the effect on gene expression is mediated directly via
the predicted MREs. We also measured BDNF levels after
transfecting two neural cell lines (ARPE-19 and U-87 MG
cells) with pre-miRs (Table 2). The majority of BDNF
transcripts in these cells contain the short 30UTR, which
should not respond to miR-155 or miR-191. Consistent
with this notion, we found that the expression of BDNF
mRNA isoforms carrying the long 30UTR was reduced
following treatment with miRs-155 and miR-191 precur-
sors, although total BDNF mRNA and BDNF protein levels
were unaffected [27].
In contrast to the above-mentioned study, Nagpal et al.
[84] found that overexpressing miR-191 increased the
expression of a luciferase reporter construct containing a
475-nt fragment of the BDNF 30UTR, which contains the
putative miR-191 site. In addition, overexpressing miR-191
increased the expression of endogenous BDNF in MCF7
cells (a breast cancer cell line), and suppressing endoge-
nous miR-191 expression using a specific antagomiR
decreased BDNF levels. However, whether the effect of
miR-191 effect on BDNF expression is direct was not
investigated [84]. Given that the dysregulation of miR-191
[85, 86] and BDNF [87–91] levels vary among different
tumor types, regulatory cofactors may determine whether
miR-191 suppresses or activates the expression of BDNF.
miR-204
Recently, Imam et al. thoroughly examined the role of
miR-204 in regulating BDNF expression. Endogenous
BDNF mRNA and protein levels were reduced after miR-
204 overexpression and increased after inhibition of
endogenous miR-204. Furthermore, miR-204 suppressed
luciferase expression via the full-length BDNF 30UTR, and
mutating the predicted binding site abolished repression by
miR-204, suggesting that BDNF is a direct target of miR-
204 [92].
miR-210
Using bioinformatics, Fasanaro et al. [93] identified BDNF
as a potential target of miR-210. However, in human
umbilical vein endothelial cells (HUVEC), neither BDNF
mRNA nor BDNF protein levels were changed by over-
expressing miR-210 or suppressing endogenous miR-210
expression. On the other hand, using HEK-293 cells the
same group found that overexpressing miR-210 and treat-
ing cells with antagomiR-210 reduced and increased BDNF
protein levels, respectively. Finally, experiments with a
luciferase construct containing either the wild-type or seed-
deleted 60-nt 30UTR fragment revealed that miR-210 binds
directly to the predicted site in the 30UTR of BDNF mRNA
[93]. In summary, the evidence to date suggests that BDNF
is a target of miR-210 under certain conditions.
Other putative BDNF-regulating miRs
In addition to the aforementioned miRs, some studies have
suggested that BDNF expression is regulated by other miRs
as well. The following miRs have been proposed as puta-
tive regulators of BDNF: miR-15a [94], miR-22 [95], miR-
26a and miR-26b [96], miR-30a [97], miR-124 [98], miR-
132, miR-182 [99], miR-195 [97], and miR-376b-5p [100].
Unfortunately, these studies lack evidence regarding (1)
whether the miR–mRNA interactions are direct and/or (2)
the effect of the respective miR on endogenous BDNF
expression (see Tables 1, 2). In addition, some of the
reported BDNF mRNA–miR interactions have not been
confirmed by independent studies [27, 82], further com-
plicating the situation and underscoring the need for a
uniform system for validating the target.
From in vitro target validation to in vivo function
Given that reduced BDNF levels are associated with sev-
eral neurological and neuropsychiatric disorders, miRs that
inhibit the expression of BDNF are attractive targets for
clinical studies. However, among the miRs that have been
shown to regulate BDNF in vitro, only miR-206 has been
reported to regulate BDNF levels in vivo [79, 81, 83].
In Alzheimer’s disease (AD), the expression of BDNF is
reduced [101, 102]. In addition, BDNF has a protective
effect against amyloid b1–42 toxicity in cultured neurons
[103] and has beneficial effects in primate and rodent
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models of AD [104]. In addition, Lee et al. [81] attempted
to increase BDNF levels in the brains of Tg2576 mice, a
mouse model of AD. Tg2576 mice overexpress a mutant
form of amyloid precursor protein; as a result, they develop
amyloid b plaques and impaired hippocampal function,
both of which are associated with deficits in cognitive
function [105]. Using a combination of microarray ana-
lysis, real-time PCR, and in situ hybridization, Lee et al.
found that the expression of miR-206 is increased in the
brains of Tg2576 mice. They also used RT-PCR to show
Table 2 Current knowledge regarding the regulation of endogenous BDNF levels by miRs
MicroRNA Effect of miR overexpression on BDNF levels compared to
control
Effect of miR suppression on BDNF levels compared
to control
References
BDNF mRNA BDNF protein BDNF mRNA BDNF protein
miR-1 20 % ; (long 30UTR only)a 20–40 % ;a n.d n.d [27]
No effectb 20–40 % ;b n.d n.d [27]
n.d 50 % ;a n.d n.d [77]
;k n.d n.d n.d [78]
miR-10b 20 % ; (long 30UTR only)a No effecta 100 % :a 20–30 % :a [27]
25 % ;b 15–40 % ;b n.d n.d [27]
miR-30a No effectc 30 % ;c n.d n.d [97]
miR-124a 50 % ;d 30-40 % ;d n.d n.d [98]
miR-132 n.d 25 % ;e n.d n.d [99]
miR-155 20–30 % ; (long 30UTR only)a b No effecta b n.d n.d [27]
miR-182 n.d 0–40 % ;e n.d n.d [99]
miR-191 20-30 % ; (long 30UTR only)a No effecta n.d n.d [27]
No effectb No effectb n.d n.d [27]
40 % :m n.d 60 % ;m n.d [84]
miR-204 70 % ;f 80 % ;f 150 % :f 100 % :f [92]
miR-206 50 % ;g n.d n.d n.d [110]
n.d 50 % ;c n.d 100 % :c [111]
n.d n.d n.d 50 % :c [83]
n.d ;e n.d :e [82]
n.d ;e h i j n.d :e h i j [81]
50 % ; (long and total 30UTR)k n.d 60 % :k n.d [80]
;k n.d n.d n.d [78]
miR-210 n.d 80 % ;f n.d 300 % :f [93]
miR-376b-5p n.d 30 % ;l n.d No effectl n [100]
n.d not determined
a U-87 MG cells
b ARPE-19 cells
c Rat primary neuronal cultures
d NG108-15 cells
e SH-SY5Y cells
f HEK293 cells
g SGC-7901 (cell line stably expressing miR-206)
h Neuro2a cells
i bEnd.3 cells
j HUVEC (human umbilical vein endothelial cells)
k C2C12 cells
l H9c2 cells
m MCF7 cells
n Compared to control; a difference in miR suppression was observed between miR-376-5p ? miR-376-5p inhibitor and miR-376-5p alone
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that miR-206 was upregulated in the temporal cortex in the
brains of patients with AD. Because in vitro experiments
suggested that BDNF is a direct target of miR-206, they
investigated the function of miR-206 in vivo by injecting
0.5 nmol of Cy3-labeled 20-O-methyl antagomiR-206
(AM206) into the third ventricle of 12-month-old Tg2576
mice, resulting in the widespread distribution of AM206
throughout the hippocampus and surrounding tissues after
24 h (shown using Cy3 fluorescence). One week after
AM206 injection, BDNF levels were increased in the
hippocampus, striatum, and cortex. AM206 injection
caused improved performance in behavioral tests that
assess memory. Furthermore, intranasal delivery of AM206
in Tg2576 mice also elevated BDNF levels in several brain
regions—including the hippocampus, striatum, and cor-
tex—and increased hippocampal memory function [81].
The findings from the above-mentioned study have clear
therapeutic potential. Unfortunately, however, data
regarding the pharmacodynamics of antagomiRs, including
the tissue distribution over time, cell type specificity, sta-
bility, clearance, and toxicity in the brain, were not
investigated. In various tissues, 20-O-methyl oligonucleo-
tides have been shown to reduce expression of their target
miR for C3 weeks [106]; however, in their study, Krutz-
feldt et al. [106] found that the antagomiRs effectively
reduced target gene levels in all tissues tested except the
brain, suggesting that intravenously injected antagomiRs
do not reach the brain or are less effective in the brain.
Recently, Jimenez-Mateos et al. [107] reported that an
intracerebroventricular injection of locked nucleic acid
(LNA)–based antagomiRs affected endogenous miR
expression in the hippocampus within 12 h. By 24 h,
endogenous miR expression was reduced by 95 % com-
pared to control-treated animals, and expression was still
reduced by 50 % 1 month after antagomiR injection; miR
expression returned to baseline levels 2 months after
treatment [107], suggesting that antagomiRs cause long-
term silencing of their target miRs in the brain, similar to
other tissues [106].
In their respective studies, Lee et al. [81] and Jimenez-
Mateos et al. [107] did not investigate the fate of antag-
omiRs in the brain; to date, antagomiR processing and
metabolism in the brain have not been examined. Thus,
several key questions remain. How do antagomiRs get into
cells in the brain? In which intracellular compartment(s) do
antagomiRs reside, and for how long? How specific are
their effects on target miRs? Do antagomiR levels correlate
temporally with the levels of their target miR and/or the
levels of the miR targets? What are the long-term conse-
quences of antagomiR treatment on gene expression and
behavior?
Results from our laboratory suggest that the fluorescent
signal from fluorophore-labeled LNA-based antagomiRs
decreases rapidly (i.e., within minutes) following direct
microinjection into primary sympathetic neurons (Fig. 4).
We also found that oligonucleotides with phosphodiester
and phosphorothioate backbones have distinct temporal
patterns of intracellular localization (Fig. 4). These results
raise several intriguing questions. For example, why does
the signal emitted by fluorophore-labeled LNA-based oli-
gonucleotides decrease within minutes in primary neurons
cultured in vitro, whereas intracranially injected fluorescent
signals can last several days (or weeks) in vivo [81, 106]?
Does the antagomiR remain linked to the fluorophore both
Fig. 4 Fluorescent signal measured from FAM-labeled LNA-based
antagomiRs. The labeled antagomiR was microinjected into primary
superior cervical ganglion neurons isolated from neonatal (P1) mice.
The images were taken at the indicated times relative to microinjec-
tion, and representative images are shown (n = 6 cells per
experiment). a Oligonucleotides on a phosphorothioate backbone
diffused slowly throughout the cytoplasm. Within several minutes, the
signal was distributed weakly throughout the entire cell. b Oligonu-
cleotides on a phosphodiester backbone diffused rapidly throughout
the cytoplasm and accumulated into the nucleus. Over time, the signal
became weaker in the cytoplasm but remained strong within the
nucleus
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in vitro and in vivo? Do these properties influence the
stability of antagomiRs and/or their effect on endogenous
miRs? These are but a few of the important questions that
must be addressed in future studies.
Toxicity from antagomiRs is another issue that must be
investigated. In their recent study, Lee et al. [81] delivered
two doses of intranasal AM206 (0.5 and 5 nmol); the lower
dose did not increase BDNF levels. Although the high dose
of AM206 caused no apparent adverse effects, it remains
unclear whether inhibiting miR-206 function resulted in an
undesirable upregulation of its other targets. Consistent
with this possibility, Lee et al. [81] found that the level of
synaptophysin—which is not a predicted target of miR-
206—was also increased after the delivery of the higher
dose of AM206, suggesting that the expression of addi-
tional genes may be affected. Given that miR-206 can act
as a tumor suppressor in several cancers, including breast
cancer [108], lung cancer [109] and stomach cancer [110],
potential side effects due to miR-206 downregulation must
be monitored closely and reported.
Conclusions
Based on in silico findings, each miR can have hundreds of
putative mRNA targets. Thus, the major challenge in study-
ing miR–target interactions is identifying which specific
interactions play a functional role in vivo. Given that even
minor differences in methodologies can yield contradictory
results, each published miR–target interaction should be
interpreted with caution, particularly when the experimental
evidence is limited. Based on the issues discussed in this
review, we propose a four-step standardized workflow plan
for studying specific miR–mRNA interactions (Fig. 5).
Moreover, we emphasize that a comprehensive description of
the methodology used can serve the scientific community
better than a brief description.
1. Identify putative miR–target interactions using in sil-
ico tools
• target prediction software [e.g., TargetScan (www.
targetscan.org), PicTar (pictar.mdc-berlin.de),
PITA (genie.weizmann.ac.il), DIANA-microT
(diana.cslab.ece.ntua.gr/microT), RNA22 (cm.jef-
ferson.edu/rna22v1.0), miRanda (www.microrna.
org)],
• existing ChIP-seq databases of endogenous miR–
target interactions [29, 30],
• expression profiles of miRs (www.microrna.org)
and their possible targets (www.genecards.org).
2. Screen miR–target interactions using a luciferase
reporter assay. To retain the full properties of the
30UTR sequence, it is preferable to use the full-length
30UTR.
Fig. 5 Recommended
workflow plan for identifying
and validating miR targets. For
details, see the text
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3. Clarify the direct interaction by performing mutation
analyses of the predicted miR-binding site within the
30UTR in the context of both exogenous and endog-
enous miR expression.
4. Measure endogenous gene expression (at the mRNA
and protein levels)
• after miR overexpression with pre-miRs or miR
mimics in primary cultures and/or cell lines,
• after suppressing endogenous miR expression in
primary cultures and/or cell lines.
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